Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Voyageur Pharmaceuticals and API Forge Alliance
View:
Post by WarrantOfficer on Mar 04, 2024 10:45am

Voyageur Pharmaceuticals and API Forge Alliance

I was pondering Voyageur's next step in our fullerene ambitions. The PR states API is "Industry funded not for profit organization". Will the Master Service Agreement (MSA) cost Voyaguer any money or is it actually free R&D that is industry funded?  If it's free, a deserved well done to the management. Not getting to far ahead of ourselves here, it states that API will be introducing Voyageurs barium contrast products. Combined with the "Scientific Advisory Board" (SAB), if it is still functional, should open up a broad pipeline of prospective customers. Lots of hype here, time will tell if management can utilize this agreement as a springboard to becoming a profitable pharama company. 



I have attached an API link. 

Business Development & Partnership Lead Generation – API (appliedpharma.ca)
Comment by whitenorth72 on Mar 04, 2024 10:50am
This is very good news. This agreement should speed up all of Voyageurs projects without further delays and negotiations. A master service agreement (MSA) is a contract that settles the general terms of future transactions or agreements. It contains the obligations and expectations of all parties involved in ongoing projects.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1